These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32291572)

  • 21. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.
    Taddei ML; Parri M; Angelucci A; Onnis B; Bianchini F; Giannoni E; Raugei G; Calorini L; Rucci N; Teti A; Bologna M; Chiarugi P
    Am J Pathol; 2009 Apr; 174(4):1492-503. PubMed ID: 19264906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.
    Wykosky J; Debinski W
    Mol Cancer Res; 2008 Dec; 6(12):1795-806. PubMed ID: 19074825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S897 phosphorylation of EphA2 is indispensable for EphA2-dependent nasopharyngeal carcinoma cell invasion, metastasis and stem properties.
    Li JY; Xiao T; Yi HM; Yi H; Feng J; Zhu JF; Huang W; Lu SS; Zhou YH; Li XH; Xiao ZQ
    Cancer Lett; 2019 Mar; 444():162-174. PubMed ID: 30583071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Overexpression of the receptor tyrosine kinase EphA2 in choroidal melanoma: correlation with vesculogenic mimicry and prognosis].
    Chen LX; Sun BC; Li XR; He YJ; Song GX
    Zhonghua Yan Ke Za Zhi; 2012 Nov; 48(11):985-90. PubMed ID: 23302271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EphrinA1 repulsive response is regulated by an EphA2 tyrosine phosphatase.
    Parri M; Buricchi F; Taddei ML; Giannoni E; Raugei G; Ramponi G; Chiarugi P
    J Biol Chem; 2005 Oct; 280(40):34008-18. PubMed ID: 16051609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model.
    Salem AF; Gambini L; Billet S; Sun Y; Oshiro H; Zhao M; Hoffman RM; Bhowmick NA; Pellecchia M
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33023262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EphA2 as a promoter of melanoma tumorigenicity.
    Margaryan NV; Strizzi L; Abbott DE; Seftor EA; Rao MS; Hendrix MJ; Hess AR
    Cancer Biol Ther; 2009 Feb; 8(3):279-88. PubMed ID: 19223760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
    Garcia-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Herrero-Martín D; Huertas-Martinez J; Lagares-Tena L; Alba-Pavón P; Hontecillas-Prieto L; Mora J; de Álava E; Rello-Varona S; Giangrande PH; Tirado OM
    Int J Cancer; 2018 Sep; 143(5):1188-1201. PubMed ID: 29582409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spatially modulated ephrinA1:EphA2 signaling increases local contractility and global focal adhesion dynamics to promote cell motility.
    Chen Z; Oh D; Biswas KH; Yu CH; Zaidel-Bar R; Groves JT
    Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5696-E5705. PubMed ID: 29866846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells.
    Sakamoto A; Kato K; Hasegawa T; Ikeda S
    Anticancer Res; 2018 Jun; 38(6):3273-3282. PubMed ID: 29848674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of EphA2/EphrinA1 signal attenuates lipopolysaccharide-induced lung injury.
    Hong JY; Shin MH; Douglas IS; Chung KS; Kim EY; Jung JY; Kang YA; Kim SK; Chang J; Kim YS; Park MS
    Clin Sci (Lond); 2016 Nov; 130(21):1993-2003. PubMed ID: 27549114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Spatial organization of EphA2 at the cell-cell interface modulates trans-endocytosis of ephrinA1.
    Greene AC; Lord SJ; Tian A; Rhodes C; Kai H; Groves JT
    Biophys J; 2014 May; 106(10):2196-205. PubMed ID: 24853748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EPHA2/EFNA1 expression in human gastric cancer.
    Nakamura R; Kataoka H; Sato N; Kanamori M; Ihara M; Igarashi H; Ravshanov S; Wang YJ; Li ZY; Shimamura T; Kobayashi T; Konno H; Shinmura K; Tanaka M; Sugimura H
    Cancer Sci; 2005 Jan; 96(1):42-7. PubMed ID: 15649254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and structure-activity relationships of amino acid conjugates of cholanic acid as antagonists of the EphA2 receptor.
    Russo S; Incerti M; Tognolini M; Castelli R; Pala D; Hassan-Mohamed I; Giorgio C; De Franco F; Gioiello A; Vicini P; Barocelli E; Rivara S; Mor M; Lodola A
    Molecules; 2013 Oct; 18(10):13043-60. PubMed ID: 24152675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EphrinA1/EphA2 Promotes Epithelial Hyperpermeability Involving in Lipopolysaccharide-induced Intestinal Barrier Dysfunction.
    Chen Y; Zhang L; Zhang Y; Bai T; Song J; Qian W; Hou X
    J Neurogastroenterol Motil; 2020 Jul; 26(3):397-409. PubMed ID: 32606260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targefrin: A Potent Agent Targeting the Ligand Binding Domain of EphA2.
    Baggio C; Udompholkul P; Gambini L; Pellecchia M
    J Med Chem; 2022 Nov; 65(22):15443-15456. PubMed ID: 36331527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of EphA2 by Dasatinib Suppresses Radiation-Induced Intestinal Injury.
    Kim A; Seong KM; Choi YY; Shim S; Park S; Lee SS
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33265912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression and prognostic significance of EphA2 and EphrinA-1 in ovarian serous carcinomas].
    Han LP; Liu JF; Liu XR; Dong ZM; Suo ZH
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):179-84. PubMed ID: 21500549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.
    Fang WB; Brantley-Sieders DM; Parker MA; Reith AD; Chen J
    Oncogene; 2005 Nov; 24(53):7859-68. PubMed ID: 16103880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis.
    Cui XD; Lee MJ; Kim JH; Hao PP; Liu L; Yu GR; Kim DG
    Hepatology; 2013 Jun; 57(6):2248-60. PubMed ID: 23315987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.